eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2016-06-25 13 2 961 965 10.13005/bbra/2121 13452 article Seyyed Javad Hosseini Shokouh 1 Mossa Ahmadi 1 Infectious Diseases Research Center, AJA Univercity of Medical Sciences, Tehran, IR Iran We examined the therapeutic effects of albendazole. metronidazole and mebenazole 183  patients with giardiasis in Tehran Province. Patients were randomized to receive albendazole (400 mg, once daily for 5 days) or metronidazole (250 mg, 3 times a day for 5 days) or mebendazole (200 mg, 2 times a day for 5 days)  . Demographic data of the patients, results of stool exa­mination for Giardia (cyst or  trophozoites ) before and after treatment, and drug side-effects were recorded. The final results showed that albendazole (93%) and mebendazole ( 89% ) and metronidazole (95.5%) have similar therapeutic effects on giardiasis . Patients in the albendazole group(19.7%) had fewer side-effects compared with metronidazole (39%) & mebendazole groups (27%) . This difference is statistically significant (p < 0.01). We offer the albendazole as a grug of choice of giardiasis. https://www.biotech-asia.org/vol13no2/albendazole-and-mebendazole-as-an-alternative-therapeutic-agent-for-adult-giardiasis/ Albendazole; Mebendazole; Metronidazole; Giardiasis; Therapy